NRx Subsidiary HOPE Therapeutics First to Deploy Advanced FDA-Cleared TMS System
NRXP has more than doubled off its 52-week low of $1.62 on elevated volume (4.2× avg).
Summary
NRx Pharmaceuticals' subsidiary, HOPE Therapeutics, is the first commercial site to deploy Zeta Surgical's FDA-cleared Zeta TMS Navigation System. This deployment at HOPE's West Palm Beach clinic enhances its interventional psychiatry platform with high-precision, image-guided treatment for depression. The move validates HOPE's integrated treatment model and is expected to set the stage for a planned trial of NRX-101 in combination with robotic-enabled TMS, linking this commercial step to NRx's core drug development pipeline. This operational progress is a positive development for a company that has recently reported 'going concern' warnings and increased cash burn.
At the time of this announcement, NRXP was trading at $4.37 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $156.1M. The 52-week trading range was $1.62 to $4.45. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.